Percheron Therapeutics Limited Stock OTC Markets
Equities
ATHJF
AU0000317281
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.012 USD | -84.00% | -.--% | +20.00% |
06-17 | Percheron Therapeutics Appoints CFO | MT |
06-03 | Percheron Therapeutics Names Chief Medical Advisor | MT |
Sales 2024 * | 3.6M 2.39M 3.28M | Sales 2025 * | 5.3M 3.52M 4.83M | Capitalization | 75.73M 50.25M 68.99M |
---|---|---|---|---|---|
Net income 2024 * | -13M -8.63M -11.84M | Net income 2025 * | -31M -20.57M -28.24M | EV / Sales 2024 * | 18.6 x |
Net cash position 2024 * | 8.92M 5.92M 8.13M | Net cash position 2025 * | 17.43M 11.56M 15.88M | EV / Sales 2025 * | 11 x |
P/E ratio 2024 * |
-5.61
x | P/E ratio 2025 * |
-2.24
x | Employees | 8 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 83.66% |
1 day | -84.00% | ||
1 month | -52.00% | ||
3 months | +20.00% | ||
6 months | -76.00% | ||
Current year | +20.00% |
Managers | Title | Age | Since |
---|---|---|---|
James Garner
CEO | Chief Executive Officer | - | 23-05-07 |
Anthony Filippis
COO | Chief Operating Officer | - | 22-10-31 |
Andrew McKenzie
PRN | Corporate Officer/Principal | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Ben Price
BRD | Director/Board Member | 68 | 21-10-03 |
James Garner
CEO | Chief Executive Officer | - | 23-05-07 |
Chairman | - | 21-03-21 |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+16.42% | 122B | |
+19.02% | 113B | |
+2.85% | 22.66B | |
-16.20% | 21.34B | |
-39.57% | 16.92B | |
-11.63% | 16.68B | |
-16.15% | 16.61B | |
+2.68% | 13.62B | |
+21.16% | 11.04B |
- Stock Market
- Equities
- PER Stock
- ATHJF Stock